News
-
-
-
-
PRESS RELEASE
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi's Qfitlia and Cablivi have been approved in China by the National Medical Products Administration, expanding care for rare diseases in the country. Qfitlia offers protection for hemophilia with as few as six injections a year, while Cablivi targets a rare life-threatening blood clotting disorder -
PRESS RELEASE
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares
Sanofi voit Qfitlia et Cablivi approuvés en Chine pour traiter les maladies rares, marquant une avancée significative avec des approbations récentes dans le domaine de l'hématologie -
-
-
-
-
